Automata – the automation company helping life sciences rapidly innovate, diagnose and discover at scale – today announces it has raised US$50 million in Series B funding. The investment round was led by Octopus Ventures with participation from returning investors Hummingbird, Latitude Ventures, ABB Technology Ventures, Isomer Capital as well as strategic investors such as In-Q-Tel, amongst others.
Automata raises US$50 Million
Automata raises US$50 Million in Series B financing to accelerate automation in Life Sciences
22nd February 2022Karen Cooper
I’m really excited at how this funding will take us on the next stage of our successful journey. At Automata we have always believed in the power of automation to support a variety of uses, especially when deployed at scale. We are thrilled to see our users adopt automation at a scale that transforms their ability to deliver more innovation in the life sciences and ultimately accelerates their pursuit of progress. For far too long scientists and clinicians have been having to work with overly complex lab solutions whereby the equipment and software are disjointed and difficult to orchestrate. Solutions are also often too rigid and inappropriate for labs with small geographic footprints. Our next generation technology solves this.
This investment will enable significant development, in the UK and beyond, of Automata Labs for scientists working across diagnostics, drug discovery and biotech. With this technology, life scientists can shorten turnaround times by scaling capacities, and spend more time on their analyses – which also leads to cost reductions.
Automata’s robotic capabilities are truly the first of its kind and the company has combined this with deep expertise in automation and a highly effective business model which has created a leading-edge over competitors. Automata Labs accelerates human ingenuity, empowering labs and scientists to achieve consistent results faster, on a greater scale, and to ultimately upscale their ambitions. We are delighted to have led this financing round as Automata represented exactly the type of highly innovative company we invest in and support. We are excited for Automata’s next steps, both within the life sciences industry, and beyond
This Series B investment is on the back of rapid growth for Automata, whose focus on the life sciences has seen nearly a million tests conducted by scientists and clinicians in recent months. Automata’s systems have been successfully utilised by NHS pathology labs to help them meet diagnostic backlogs and upscale capacity, with one of these labs running 40 fully automated stations 24/7. Scientists who have used Automata Labs report that they are able to achieve consistently accurate results faster, and on a larger scale, than before. Automata is also currently advising and deploying automation with contract research organisations, research labs and leading blue chip healthcare institutions.
We sit down with Marko Storch, Head of Synthetic Biology and Automation, London Biofoundry, to talk about tackling the challenges of lab-grown meat
This ebook explores the challenges for cell culture labs, how to overcome them, and the benefits of automated cell culture